|
GB0401398D0
|
|
New theraputic use
|
|
GB0316115D0
|
|
New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno [2,3-d]pyrimidine
|
|
BR0312511A
|
|
4- (2-fluorophenyl) -6-methyl-2- (1-piperazinyl) thieno [2,3-d] pyrimidine in the treatment of functional bowel disorder
|
|
GB0306859D0
|
|
Topical formulation and use of buspirone
|
|
GB0304648D0
|
|
New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl)thieno(2,3-D)pyrimidine
|
|
GB0229744D0
|
|
New therapeutic use
|
|
EP1465622A1
|
|
Use of ppar activators for the treatment of pulmonary fibrosis
|
|
JP2004168692A
|
|
New use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2, 3-d]pyrimidine
|
|
WO03030903A1
|
|
The use of tizanidine for treating metabolic disorders related to abnormal insulin secretion
|
|
GB0222478D0
|
|
New therapeutic use
|
|
GB0220064D0
|
|
New therapeutic use
|
|
GB0216128D0
|
|
New therapeutic use
|
|
GB0216027D0
|
|
New therapeutic use
|
|
MXPA03011226A
|
|
Arylazo-substituted imidazole for the treatment of stress urinary incontinence.
|
|
EP1385516A1
|
|
The treatment of scarring and related conditions using ppar-gamma activators
|
|
GB0202265D0
|
|
New therapeutic use
|
|
GB0128300D0
|
|
New therapeutic use
|
|
GB0128304D0
|
|
New therapeutic use
|
|
GB0112491D0
|
|
New therapeutic use
|
|
GB0112494D0
|
|
New therapeutic use
|
